Lirilumab (INN) is a human monoclonal antibody designed for the treatment of cancer. It binds to KIR2DL1/2/3.
Lirilumab (INN) is a human monoclonal antibody designed for the treatment of cancer. It binds to KIR2DL1/2/3.
This drug was developed by Innate Pharma and is licensed to Bristol-Myers Squibb.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).